menu
    • menu
    [{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"H3B-6545","moa":"Selective estrogen receptor covalent","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"H3 Biomedicine Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H3 Biomedicine Inc \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"H3 Biomedicine Inc \/ Not Applicable"},{"orgOrder":0,"company":"H3 Biomedicine Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"E7766","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"H3 Biomedicine Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"H3 Biomedicine Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"H3 Biomedicine Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by H3 Biomedicine Inc

    Menu

    H3 Biomedicine Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            H3 Biomedicine Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            H3 Biomedicine Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : E7766

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program for Advanced Solid Tumors or Lymphomas a...

                            Details : E7766 is a STING (Stimulator of Interferon Genes) agonist with broad specificity to all major genetic variants of human STING. Preclinical studies suggest that treatment with E7766 by intratumoral administration has anti-tumor activity at both local and ...

                            Brand Name : E7766

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2021

                            Lead Product(s) : E7766

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            H3 Biomedicine Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            H3 Biomedicine Inc

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : H3B-6545

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            H3 Biomedicine Presents Data Update on H3B-6545 at San Antonio Breast Cancer Symposium

                            Details : The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.

                            Brand Name : H3B-6545

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 08, 2020

                            Lead Product(s) : H3B-6545

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth